login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MERUS NV (MRUS) Stock News
USA
- NASDAQ:MRUS -
NL0011606264
-
Common Stock
95.23
USD
+0.07 (+0.07%)
Last: 11/7/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MRUS Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Merus N.V.
Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
16 days ago - By: Merus N.V.
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
16 days ago - By: Merus N.V.
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
a month ago - By: EQT
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
a month ago - By: Stocktwits
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal
a month ago - By: Benzinga
- Mentions:
GMAB
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
17 days ago - By: Halper Sadeh LLC
- Mentions:
MTSR
HOLX
HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
17 days ago - By: Kahn Swick & Foti, LLC
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
25 days ago - By: Merus N.V.
Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker
26 days ago - By: Merus N.V.
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
26 days ago - By: Merus N.V.
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
a month ago - By: Merus N.V.
Merus kondigt de selectie aan van het abstract: Petosemtamab in Metastatic Colorectal Cancer (petosemtamab in gemetastaseerde colorectale kanker) voor mondelinge presentatie in de plenaire sessie op de AACR-NCI-EORTC International Conference on Molecular
a month ago - By: Merus N.V.
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
a month ago - By: Merus N.V.
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
a month ago - By: Halper Sadeh LLC
- Mentions:
PINC
ODP
PRO
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders
a month ago - By: Halper Sadeh LLC
- Mentions:
EA
BRY
SMLR
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
a month ago - By: Brodsky & Smith LLC
- Mentions:
EA
GMAB
BRY
CRC
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
a month ago - By: Halper Sadeh LLC
- Mentions:
PRO
EA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders
a month ago - By: Halper Sadeh LLC
- Mentions:
EA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders
a month ago - By: Kahn Swick & Foti, LLC
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
a month ago - By: Benzinga
- Mentions:
CART
EA
U
SPOT
This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
a month ago - By: Halper Sadeh LLC
- Mentions:
EA
BRY
SMLR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
a month ago - By: Brodsky & Smith LLC
- Mentions:
EA
BRY
SMLR
GMAB
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
a month ago - By: Investor's Business Daily
- Mentions:
PFE
AAPL
GMAB
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
a month ago - By: Halper Sadeh LLC
MRUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Merus N.V. Is Fair to Shareholders
Please enable JavaScript to continue using this application.
